Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Biolase (NASDAQ:BIOL) Share Price
News stories about Biolase (NASDAQ:BIOL) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Biolase earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news stories about the medical technology company an impact score of 46.3478623301468 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Edited Transcript of BIOL earnings conference call or presentation 7-Aug-17 8:30pm GMT (finance.yahoo.com)
- New report examines Asia Pacific’s dental equipment market is projected to reach $ 1,564 million by 2021 (whatech.com)
- ETFs with exposure to BIOLASE, Inc. : August 8, 2017 (finance.yahoo.com)
- Biolase, Inc. (BIOL) Releases Earnings Results, Misses Estimates By $0.04 EPS (americanbankingnews.com)
- Dental Diagnostic & Surgical Equipment Market Report – Actionable Insights and Recommendation (openpr.com)
Shares of Biolase (NASDAQ BIOL) traded down 28.05% on Tuesday, hitting $0.59. 716,239 shares of the stock traded hands. The stock has a 50 day moving average of $0.91 and a 200-day moving average of $1.22. The stock’s market cap is $39.92 million. Biolase has a 1-year low of $0.59 and a 1-year high of $1.98.
Biolase (NASDAQ:BIOL) last announced its earnings results on Monday, August 7th. The medical technology company reported ($0.06) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by $0.04. Biolase had a negative net margin of 29.44% and a negative return on equity of 65.77%. The company had revenue of $12.61 million during the quarter. On average, equities research analysts expect that Biolase will post ($0.14) EPS for the current year.
Several research analysts have recently issued reports on the stock. Singular Research assumed coverage on shares of Biolase in a research note on Tuesday, April 25th. They issued a “buy” rating and a $2.50 target price on the stock. ValuEngine lowered shares of Biolase from a “hold” rating to a “sell” rating in a research note on Monday, July 24th.
WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/08/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-biolase-nasdaqbiol-share-price.html.
Biolase Company Profile
BIOLASE, Inc (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers.
Receive News & Ratings for Biolase Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biolase Inc. and related companies with MarketBeat.com's FREE daily email newsletter.